P-222: Extended follow-up safety and efficacy results of Belantamab mafodotin (Belamaf) 1.92 mg/kg or 2.5 mg/kg combined with POM and DEX for the treatment of relapsed/refractory Multiple Myeloma
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI